Hörer Stefan, Reinert Dirk, Ostmann Katja, Hoevels Yvette, Nar Herbert
Department of Lead Identification and Optimization Support, Boehringer Ingelheim Pharma GmbH and Co KG, Birkendorferstrasse 65, 88400 Biberach, Germany.
Acta Crystallogr Sect F Struct Biol Cryst Commun. 2013 Jun;69(Pt 6):592-6. doi: 10.1107/S174430911301124X. Epub 2013 May 23.
Keap1 is a substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex and plays an important role in the cellular response to oxidative stress. It binds Nrf2 with its Kelch domain and thus triggers the ubiquitinylation and degradation of Nrf2. Oxidative stress prevents the degradation of Nrf2 and leads to the activation of cytoprotective genes. Therefore, Keap1 is an attractive drug target in inflammatory diseases. The support of a medicinal chemistry effort by structural research requires a robust crystallization system in which the crystals are preferably suited for performing soaking experiments. This facilitates the generation of protein-ligand complexes in a routine and high-throughput manner. The structure of human Keap1 has been described previously. In this crystal form, however, the binding site for Nrf2 was blocked by a crystal contact. This interaction was analysed and mutations were introduced to disrupt this crystal contact. One double mutation (E540A/E542A) crystallized in a new crystal form in which the binding site for Nrf2 was not blocked and was accessible to small-molecule ligands. The crystal structures of the apo form of the mutated Keap1 Kelch domain (1.98 Å resolution) and of the complex with an Nrf2-derived peptide obtained by soaking (2.20 Å resolution) are reported.
Keap1是一种Cul3依赖性泛素连接酶复合物的底物衔接蛋白,在细胞对氧化应激的反应中起重要作用。它通过其kelch结构域与Nrf2结合,从而触发Nrf2的泛素化和降解。氧化应激可防止Nrf2的降解并导致细胞保护基因的激活。因此,Keap1是炎症性疾病中一个有吸引力的药物靶点。通过结构研究支持药物化学研究需要一个强大的结晶系统,其中晶体最好适合进行浸泡实验。这有助于以常规和高通量的方式生成蛋白质-配体复合物。人Keap1的结构先前已有描述。然而,在这种晶体形式中,Nrf2的结合位点被晶体接触所阻断。对这种相互作用进行了分析,并引入突变以破坏这种晶体接触。一个双突变体(E540A/E542A)以一种新的晶体形式结晶,其中Nrf2的结合位点未被阻断,小分子配体可接近该位点。报道了突变的Keap1 kelch结构域的无配体形式(分辨率为1.98 Å)和通过浸泡获得的与Nrf2衍生肽的复合物的晶体结构(分辨率为2.20 Å)。